Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · IEX Real-Time Price · USD
5.53
-0.31 (-5.39%)
Apr 19, 2024, 2:49 PM EDT - Market open
Aprea Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aprea Therapeutics stock have an average target of 15.5, with a low estimate of 11 and a high estimate of 20. The average target predicts an increase of 180.54% from the current stock price of 5.53.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for APRE stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $9 → $11 | Buy | Maintains | $9 → $11 | +99.10% | Mar 27, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +261.99% | Mar 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +261.99% | Nov 1, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +261.99% | Sep 13, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +261.99% | Aug 10, 2023 |
Financial Forecast
Revenue This Year
306.00K
from 583.23K
Decreased by -47.53%
Revenue Next Year
306.00K
from 306.00K
EPS This Year
-2.42
from -3.95
EPS Next Year
-0.98
from -2.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 630,000 | 630,000 | 630,000 | 76.6M | 157.3M |
| Avg | 306,000 | 306,000 | 306,000 | 25.1M | 58.0M |
| Low | n/a | n/a | n/a | n/a | 8.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 8.0% | 105.9% | 105.9% | 24,939.9% | 527.3% |
| Avg | -47.5% | - | - | 8,097.1% | 131.2% |
| Low | - | - | - | - | -64.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.46 | -0.61 | -0.64 | -1.28 | -1.26 |
| Avg | -2.42 | -0.98 | -1.06 | -1.24 | -1.22 |
| Low | -3.29 | -1.31 | -1.43 | -1.20 | -1.18 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.